Literature DB >> 16887847

Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab.

M Bassetti, C Pizzorni, L Gradoni, V Del Bono, M Cutolo, C Viscoli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16887847     DOI： 10.1093/rheumatology/kel235

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  9 in total

1.  Let off the leash: kala-azar following the use of tumour necrosis factor antibodies.

Authors:  Anjum Khan; Gerald Coakley; Catherine Cosgrove; Diana Lockwood
Journal:  BMJ Case Rep       Date:  2010-10-13

2.  Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?

Authors:  Maria G Tektonidou; Fotini N Skopouli
Journal:  Clin Rheumatol       Date:  2007-10-26       Impact factor: 2.980

3.  Is Visceral Leishmaniasis Different in Immunocompromised Patients Without Human Immunodeficiency Virus? A Comparative, Multicenter Retrospective Cohort Analysis.

Authors:  José M Ramos; Rafael León; Esperanza Merino; Marta Montero; Asunción Aljibe; Marino Blanes; Sergio Reus; Vicente Boix; Miguel Salavert; Joaquín Portilla
Journal:  Am J Trop Med Hyg       Date:  2017-10-10       Impact factor: 2.345

4.  Five-year retrospective Italian multicenter study of visceral leishmaniasis treatment.

Authors:  Francesco Di Masi; Tamara Ursini; Maria Donata Iannece; Leonardo Chianura; Francesco Baldasso; Giuseppe Foti; Pietro Di Gregorio; Angelo Casabianca; Nunzio Storaci; Luciano Nigro; Claudia Colomba; Maria Grazia Marazzi; Giovanni Todaro; Giacinta Tordini; Giacomo Zanelli; Giovanni Cenderello; Nicola Acone; Ennio Polilli; Simona Migliore; Paolo Almi; Eligio Pizzigallo; Evangelista Sagnelli; Francesco Mazzotta; Rosario Russo; Lamberto Manzoli; Giustino Parruti
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

Review 5.  Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy.

Authors:  Alti Dayakar; Sambamurthy Chandrasekaran; Suresh V Kuchipudi; Suresh K Kalangi
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

6.  Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression.

Authors:  Pau Bosch-Nicolau; Maria Ubals; Fernando Salvador; Adrián Sánchez-Montalvá; Gloria Aparicio; Alba Erra; Pablo Martinez de Salazar; Elena Sulleiro; Israel Molina
Journal:  PLoS Negl Trop Dis       Date:  2019-08-30

Review 7.  Leishmaniasis in the United States: Emerging Issues in a Region of Low Endemicity.

Authors:  John M Curtin; Naomi E Aronson
Journal:  Microorganisms       Date:  2021-03-11

Review 8.  Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe.

Authors:  Ioannis D Xynos; Maria G Tektonidou; Dimitrios Pikazis; Nikolaos V Sipsas
Journal:  Emerg Infect Dis       Date:  2009-06       Impact factor: 6.883

9.  Leishmania infantum amastigotes enhance HIV-1 production in cocultures of human dendritic cells and CD4 T cells by inducing secretion of IL-6 and TNF-alpha.

Authors:  Ravendra Garg; Corinne Barat; Michel Ouellet; Robert Lodge; Michel J Tremblay
Journal:  PLoS Negl Trop Dis       Date:  2009-05-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.